Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: The evidence, etiology, and therapeutic challenges

Current Atherosclerosis Reports

Volumn 14, Issue 1, 2012, Pages 1-10

  Sampson, Uchechukwu K ^a   Fazio, Sergio ^a   Linton, MacRae F ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CV risk reduction; LDL cholesterol; Residual CV risk; Statins

Indexed keywords

ANACETRAPIB; ATORVASTATIN; DALCETRAPIB; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; AEROBIC EXERCISE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK REDUCTION; SMOKING CESSATION; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MORBIDITY; RISK ASSESSMENT; RISK FACTORS;

EID: 84857637931     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0219-7     Document Type: Article

References (105)

1. C Baigent L Blackwell J Emberson, et al. 2010 Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 1670 1681 21067804 1:STN:280:DC%2BC3cbmvVGmsQ%3D%3D 10.1016/S0140-6736(10)61350-5 This is the strongest available meta-analysis on the value of intensive LDL-C lowering in reducing cardiovascular risk
2. SC Smith Jr J Allen SN Blair, et al. 2006 AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute J Am Coll Cardiol 47 2130 2139 16697342 10.1016/j.jacc.2006.04.026 (Pubitemid 44275145)
3. SM Grundy JI Cleeman CN Merz, et al. 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 227 239 15249516 10.1161/01.CIR.0000133317.49796.0E (Pubitemid 38924592)
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
5. I Graham D Atar K Borch-Johnsen, et al. 2007 European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur Heart J 28 2375 2414 17726041 10.1093/eurheartj/ehm316 (Pubitemid 47542237)
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-57.
8. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
9. JR Downs M Clearfield S Weis, et al. 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1615 1622 9613910 1:STN:280:DyaK1c3ntl2qsw%3D%3D 10.1001/jama.279.20.1615 (Pubitemid 28248586)
10. FM Sacks MA Pfeffer LA Moye, et al. 1996 The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1001 1009 8801446 1:CAS:528:DyaK28XmsFWls7c%3D 10.1056/NEJM199610033351401 (Pubitemid 26338729)
11. J Shepherd SM Cobbe I Ford, et al. 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1301 1307 7566020 1:CAS:528:DyaK28Xhslemsw%3D%3D 10.1056/NEJM199511163332001
12. P Libby 2005 The forgotten majority: unfinished business in cardiovascular risk reduction J Am Coll Cardiol 46 1225 1228 16198835 10.1016/j.jacc.2005.07.006 (Pubitemid 41615541)
13. CP Cannon E Braunwald CH McCabe, et al. 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 1495 1504 15007110 1:CAS:528:DC%2BD2cXjtVeqtr8%3D 10.1056/NEJMoa040583 (Pubitemid 38477774)
14. JC LaRosa SM Grundy DD Waters, et al. 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 1425 1435 15755765 1:CAS:528:DC%2BD2MXjtVWltrw%3D 10.1056/NEJMoa050461 (Pubitemid 40471450)
15. TR Pedersen O Faergeman JJ Kastelein, et al. 2005 High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2437 2445 16287954 1:CAS:528:DC%2BD2MXht1aku7jK 10.1001/jama.294.19.2437 (Pubitemid 41627921)
16. JA de Lemos MA Blazing SD Wiviott, et al. 2004 Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 1307 1316 15337732 10.1001/jama.292.11.1307 (Pubitemid 39223221)
17. CP Cannon BA Steinberg SA Murphy, et al. 2006 Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 438 445 16875966 1:CAS:528:DC%2BD28XntlWjsLo%3D 10.1016/j.jacc.2006.04.070 (Pubitemid 44109954)
18. C Baigent A Keech PM Kearney, et al. 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278 16214597 1:CAS:528:DC%2BD2MXhtVOlu7fM 10.1016/S0140-6736(05)67394-1 (Pubitemid 41416582)
19. V Sazonov J Beetsch H Phatak, et al. 2010 Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database Atherosclerosi 208 210 216 1:CAS:528:DC%2BC3cXkt1CjtQ%3D%3D 10.1016/j.atherosclerosis.2009.07.021 This is a retrospective cohort study that demonstrated the association between low HDL-C and/or elevated TG and cardiovascular events despite statin treatment for LDL-C reduction
20. BJ Arsenault P Barter DA DeMicco, et al. 2011 Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers J Am Coll Cardiol 57 63 69 21185503 1:CAS:528: DC%2BC3MXhtlartL0%3D 10.1016/j.jacc.2010.06.052
21. BG Brown XQ Zhao A Chait, et al. 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 1583 1592 11757504 1:CAS:528:DC%2BD3MXoslyhsLs%3D 10.1056/NEJMoa011090 (Pubitemid 33126837)
22. G Brown JJ Albers LD Fisher, et al. 1990 Regression of coronary artery disease as a result of intensive lipid- lowering therapy in men with high levels of apolipoprotein B [see comments] N Engl J Med 323 1289 1298 2215615 1:STN:280:DyaK3M%2FhsFaksw%3D%3D 10.1056/NEJM199011083231901 (Pubitemid 20364735)
23. HB Rubins SJ Robins D Collins, et al. 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 410 418 10438259 1:CAS:528:DyaK1MXltlyltbw%3D 10.1056/NEJM199908053410604 (Pubitemid 29362514)
24. Z Chen R Peto R Collins, et al. 1991 Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations BMJ 303 276 282 1888927 1:STN:280:DyaK3Mzmtl2nuw%3D%3D 10.1136/bmj.303.6797.276
25. J Stamler O Vaccaro JD Neaton D Wentworth 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 434 444 8432214 1:STN:280:DyaK3s7mtFyrtQ%3D%3D 10.2337/diacare.16.2.434 (Pubitemid 23046633)
26. FM Sacks AM Tonkin J Shepherd, et al. 2000 Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 102 1893 1900 11034935 1:CAS:528:DC%2BD3cXnvV2qtL0%3D
27. T Gordon WP Castelli MC Hjortland, et al. 1977 High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 707 714 193398 1:CAS:528:DyaE2sXhvVOhtbg%3D 10.1016/0002-9343(77)90874-9 (Pubitemid 8110784)
28. DJ Gordon JL Probstfield RJ Garrison, et al. 1989 High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 8 15 2642759 1:STN:280:DyaL1M%2FptVWjtg%3D%3D 10.1161/01.CIR.79.1.8 (Pubitemid 19043669)
29. JJ Genest Jr SS Martin-Munley JR McNamara, et al. 1992 Familial lipoprotein disorders in patients with premature coronary artery disease Circulation 85 2025 2033 1534286
30. JJ Genest JR McNamara DN Salem EJ Schaefer 1991 Prevalence of risk factors in men with premature coronary artery disease Am J Cardiol 67 1185 1189 2035438 1:STN:280:DyaK3M3ktFSisA%3D%3D 10.1016/0002-9149(91)90924-A
31. G Assmann H Schulte A von Eckardstein Y Huang 1996 High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 124 Suppl S11 S20 8831911 1:CAS:528:DyaK28XjvFGqtb4%3D 10.1016/0021-9150(96)05852-2 (Pubitemid 26268441)
32. AR Sharrett CM Ballantyne SA Coady, et al. 2001 Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study Circulation 104 1108 1113 11535564 1:CAS:528:DC%2BD3MXotlWgur0%3D 10.1161/hc3501.095214 (Pubitemid 32830392)
33. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
34. E Bruckert M Baccara-Dinet F McCoy J Chapman 2005 High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients Curr Med Res Opin 21 1927 1934 16368042 1:CAS:528:DC%2BD28XhtF2jurY%3D 10.1185/030079905X74871 (Pubitemid 41803102)
35. ES Ford WH Giles WH Dietz 2002 Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 287 356 359 11790215 10.1001/jama.287.3.356 (Pubitemid 34251969)
36. H Jafri AA Alsheikh-Ali RH Karas 2010 Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk Ann Intern Med 153 800 808 21173414 This is the strongest available meta-analysis showing the persistent relationship between low HDL-C and cardiovascular risk despite statin therapy
37. P Barter AM Gotto JC LaRosa, et al. 2007 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 1301 1310 17898099 1:CAS:528:DC%2BD2sXhtFSmtr3M 10.1056/NEJMoa064278 (Pubitemid 47481452)
38. KK Ray CP Cannon R Cairns, et al. 2009 Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arterioscler Thromb Vasc Biol 29 424 430 19122170 1:CAS:528:DC%2BD1MXhs1Cgt7k%3D 10.1161/ATVBAHA.108.181735
39. PM Ridker J Genest SM Boekholdt, et al. 2010 HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 333 339 20655105 1:CAS:528:DC%2BC3cXpsFenurs%3D 10.1016/S0140-6736(10)60713-1
40. RJ Garrison WB Kannel M Feinleib, et al. 1978 Cigarette smoking and HDL cholesterol: the Framingham offspring study Atherosclerosis 30 17 25 209795 1:CAS:528:DyaE1cXlt1Cgsr0%3D 10.1016/0021-9150(78)90149-1 (Pubitemid 8341515)
41. K Maeda Y Noguchi T Fukui 2003 The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis Prev Med 37 283 290 14507483 1:CAS:528:DC%2BD3sXnsVWruro%3D 10.1016/S0091-7435(03)00110-5 (Pubitemid 37162679)
42. LA Carlson A Hamsten A Asplund 1989 Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid J Intern Med 226 271 276 2530298 1:STN:280:DyaK3c%2FjvFWjsQ%3D%3D 10.1111/j.1365-2796.1989.tb01393.x (Pubitemid 19230908)
43. AM Dattilo PM Kris-Etherton 1992 Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis Am J Clin Nutr 56 320 328 1386186 1:CAS:528:DyaK38XlslSju7Y%3D
44. RC Ellison Y Zhang MM Qureshi, et al. 2004 Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study Am Heart J 147 529 535 14999205 1:CAS:528:DC%2BD2cXhslensLg%3D 10.1016/j.ahj.2003.10.033 (Pubitemid 38880878)
45. WP James A Astrup N Finer, et al. 2000 Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance Lancet 356 2119 2125 11191537 1:CAS:528:DC%2BD3MXitlGhtQ%3D%3D 10.1016/S0140-6736(00)03491-7 (Pubitemid 32047947)
46. F Karpe KN Frayn 2004 The nicotinic acid receptor-a new mechanism for an old drug Lancet 363 1892 1894 15183629 1:CAS:528:DC%2BD2cXks1ert7s%3D 10.1016/S0140-6736(04)16359-9 (Pubitemid 38748647)
47. AH Lichtenstein 2003 Dietary fat and cardiovascular disease risk: quantity or quality? J Womens Health (Larchmt) 12 109 114 10.1089/ 154099903321576493 (Pubitemid 36546754)
48. K Meksawan DR Pendergast JJ Leddy, et al. 2004 Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women J Am Coll Nutr 23 131 140 15047679 (Pubitemid 38405971)
49. C Couillard JP Despres B Lamarche, et al. 2001 Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study Arterioscler Thromb Vasc Biol 21 1226 1232 11451756 1:CAS:528:DC%2BD3MXltlKmurY%3D 10.1161/hq0701.092137 (Pubitemid 34215155)
50. AC King WL Haskell DR Young, et al. 1995 Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years Circulation 91 2596 2604 7743622 1:CAS:528:DyaK2MXms12nsr4%3D
51. PD Thompson 1990 What do muscles have to do with lipoproteins? Circulation 81 1428 1430 2317921 1:STN:280:DyaK3c3gtVWgtA%3D%3D 10.1161/01.CIR.81.4.1428 (Pubitemid 20119645)
52. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102:21-7.
53. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-10.
54. A Keech RJ Simes P Barter, et al. 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 1849 1861 16310551 1:STN:280:DC%2BD2MnjtVCnsg%3D%3D 10.1016/S0140-6736(05)67667-2 (Pubitemid 41690113)
55. V Manninen MO Elo MH Frick, et al. 1988 Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study JAMA 260 641 651 3164788 1:STN:280:DyaL1c3nsFWjsQ%3D%3D 10.1001/jama.1988.03410050061031
56. TA Jacobson MM Chin GJ Fromell, et al. 1994 Fluvastatin with and without niacin for hypercholesterolemia Am J Cardiol 74 149 154 8023779 1:STN:280:DyaK2c3psFGisw%3D%3D 10.1016/0002-9149(94)90088-4 (Pubitemid 24219302)
57. JH O'Keefe Jr WS Harris J Nelson SL Windsor 1995 Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia Am J Cardiol 76 480 484 7653448 10.1016/S0002-9149(99)80134-9
58. SF Gardner EF Schneider MC Granberry IR Carter 1996 Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin Pharmacotherapy 16 419 423 8726600 1:STN:280:DyaK28zjs1Ontw%3D%3D (Pubitemid 26161343)
59. DM Capuzzi JM Morgan RJ Weiss, et al. 2003 Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels Am J Cardiol 91 1304 1310 12767421 1:CAS:528:DC%2BD3sXktFGlsrk%3D 10.1016/S0002-9149(03)00318-7 (Pubitemid 36593473)
60. W Insull Jr ME McGovern H Schrott, et al. 2004 Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis Arch Intern Med 164 1121 1127 15159270 1:CAS:528:DC%2BD2cXltVGntr0%3D 10.1001/archinte.164.10.1121 (Pubitemid 38668992)
61. DB Hunninghake ME McGovern M Koren, et al. 2003 A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin Clin Cardiol 26 112 118 12685616 10.1002/clc.4960260304 (Pubitemid 36330859)
62. AJ Taylor LE Sullenberger HJ Lee, et al. 2004 Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 3512 3517 15537681 1:CAS:528:DC%2BD2MXhtVGnt7s%3D 10.1161/01.CIR.0000148955.19792.8D (Pubitemid 39612564)
63. AJ Taylor HJ Lee LE Sullenberger 2006 The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2243 2250 17076985 1:CAS:528:DC%2BD28XhtlCku7jK 10.1185/030079906X148508 (Pubitemid 44789989)
64. M Navab GM Anantharamaiah ST Reddy AM Fogelman 2006 Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention Nat Clin Pract Cardiovasc Med 3 540 547 16990839 1:CAS:528:DC%2BD28XhtFChtLfF 10.1038/ncpcardio0661 (Pubitemid 44445797)
65. M Navab GM Anantharamaiah ST Reddy, et al. 2004 Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice Circulation 109 3215 3220 15197147 1:CAS:528:DC%2BD2cXltVCgtrg%3D 10.1161/01.CIR.0000134275.90823.87
66. M Navab GM Anantharamaiah S Hama, et al. 2002 Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol Circulation 105 290 292 11804981 1:CAS:528:DC%2BD38XhsFSgt7k%3D 10.1161/hc0302.103711 (Pubitemid 34106174)
67. DW Garber G Datta M Chaddha, et al. 2001 A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis J Lipid Res 42 545 552 11290826 1:CAS:528:DC%2BD3MXjtFSitbY%3D (Pubitemid 32366997)
68. SE Nissen T Tsunoda EM Tuzcu, et al. 2003 Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2292 2300 14600188 1:CAS:528: DC%2BD3sXovVCjtbc%3D 10.1001/jama.290.17.2292 (Pubitemid 37430562)
69. MH Davidson 2011 Apolipoprotein A-I therapy promise, challenges, and disappointment J Am Coll Cardiol 57 1120 1121 21255956 10.1016/j.jacc.2010.11. 025
70. GG Schwartz AG Olsson CM Ballantyne, et al. 2009 Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome Am Heart J 158 896 901 e3 19958854 1:CAS:528:DC%2BD1MXhsFagsr7K 10.1016/j.ahj.2009.09.017
71. ME Brousseau EJ Schaefer ML Wolfe, et al. 2004 Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 1505 1515 15071125 1:CAS:528:DC%2BD2cXjtVeqt7Y%3D 10.1056/NEJMoa031766 (Pubitemid 38477775)
72. GJ de Grooth JA Kuivenhoven AF Stalenhoef, et al. 2002 Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study Circulation 105 2159 2165 11994249 10.1161/01.CIR.0000015857.31889.7B (Pubitemid 34517159)
73. PJ Barter M Caulfield M Eriksson, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 17984165 1:CAS:528:DC%2BD2sXhtlGns7bL 10.1056/NEJMoa0706628 (Pubitemid 350146106)
74. M Vergeer ML Bots SI van Leuven, et al. 2008 Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials Circulation 118 2515 2522 19029469 1:CAS:528: DC%2BD1cXhsVerur3K 10.1161/CIRCULATIONAHA.108.772665
75. MA Miyares 2011 Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors Ann Pharmacother 45 84 94 21205945 1:CAS:528:DC%2BC3MXhsFWju7g%3D 10.1345/aph.1P446
76. PL Canner CD Furberg ML Terrin ME McGovern 2005 Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol 95 254 257 15642562 1:CAS:528:DC%2BD2MXisF2isA%3D%3D 10.1016/j.amjcard.2004.09.013 (Pubitemid 40092094)
77. E Bruckert J Labreuche P Amarenco 2010 Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 353 361 20079494 1:CAS:528: DC%2BC3cXmslGnu78%3D 10.1016/j.atherosclerosis.2009.12.023 This is the strongest available meta-analysis on the beneficial effects of nicotinic acid in reducing cardiovascular risk
78. AV Khera M Cuchel M de la Llera-Moya, et al. 2011 Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 127 135 21226578 1:CAS:528:DC%2BC3MXmvFarsA%3D%3D 10.1056/NEJMoa1001689 This article provides strong evidence that the functionality of HDL, independent of HDL-C level, has a strong inverse association with atherosclerotic cardiovascular disease
79. N Sarwar J Danesh G Eiriksdottir, et al. 2007 Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 450 458 17190864 1:CAS:528:DC%2BD2sXnvF2ntQ%3D%3D 10.1161/CIRCULATIONAHA.106.637793 (Pubitemid 46184196)
80. M Miller CP Cannon SA Murphy, et al. 2008 Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 51 724 730 18279736 1:CAS:528:DC%2BD1cXitVWlsb0%3D 10.1016/j.jacc.2007.10.038 (Pubitemid 351221217)
81. FM Sacks 2008 After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate Am J Cardiol 102 34L 40L 19084088 1:CAS:528:DC%2BD1MXhtlenur0%3D 10.1016/j.amjcard.2008.09.073
82. HN Ginsberg MB Elam LC Lovato, et al. 2010 Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 1563 1574 20228404 10.1056/NEJMoa1001282
83. PJ Barter KA Rye 2008 Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 28 39 46 17717290 1:CAS:528:DC%2BD2sXhsVeiu7nJ 10.1161/ATVBAHA.107.148817
84. M Elam LC Lovato H Ginsberg 2011 Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective Curr Opin Lipidol 22 55 61 21102326 1:CAS:528:DC%2BC3MXlsFWqsg%3D%3D 10.1097/MOL.0b013e328341a5a8
85. Y Cui RS Blumenthal JA Flaws, et al. 2001 Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 161 1413 1419 11386890 1:STN:280:DC%2BD3MvjsFygtA%3D%3D 10.1001/archinte.161.11.1413 (Pubitemid 32681162)
86. R Jiang MB Schulze T Li, et al. 2004 Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes Diabetes Care 27 1991 1997 15277429 1:CAS:528:DC%2BD2cXntVygt7c%3D 10.2337/diacare.27.8.1991 (Pubitemid 38989244)
87. J Liu C Sempos RP Donahue, et al. 2005 Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes Diabetes Care 28 1916 1921 16043732 10.2337/diacare.28.8.1916 (Pubitemid 41060963)
88. PM Ridker N Rifai NR Cook, et al. 2005 Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women JAMA 294 326 333 16030277 1:CAS:528:DC%2BD2MXmtlGks78%3D 10.1001/jama.294.3.326 (Pubitemid 41043776)
89. J Liu CT Sempos RP Donahue, et al. 2006 Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease Am J Cardiol 98 1363 1368 17134630 1:CAS:528: DC%2BD28XhtFKmtLzE 10.1016/j.amjcard.2006.06.032 (Pubitemid 44666646)
90. S Yusuf S Hawken S Ounpuu, et al. 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 937 952 15364185 10.1016/S0140-6736(04)17018-9 (Pubitemid 39208455)
91. J Shepherd J Betteridge L Van Gaal 2005 Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel Curr Med Res Opin 21 665 682 15969866 1:CAS:528:DC%2BD2MXlslakt7o%3D 10.1185/030079905X43677 (Pubitemid 40695288)
92. PM Kearney L Blackwell R Collins, et al. 2008 Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 117 125 18191683 1:STN:280:DC%2BD1c%2FjvVWmsg%3D%3D 10.1016/S0140-6736(08)60761-8 (Pubitemid 351697949)
93. PM Ridker E Danielson FA Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 2207 18997196 1:CAS:528:DC%2BD1cXhtl2gurnL 10.1056/NEJMoa0807646
94. PM Ridker E Danielson FA Fonseca, et al. 2009 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 1175 1182 19329177 1:CAS:528:DC%2BD1MXktV2gsL8%3D 10.1016/S0140-6736(09)60447-5 This article provides clinical trial evidence for the relationship between inflammation, LDL-C, and cardiovascular events in patients with low LDL-C but elevated hs-CRP
95. P Libby PM Ridker A Maseri 2002 Inflammation and atherosclerosis Circulation 105 1135 1143 11877368 1:CAS:528:DC%2BD38XislWhu7k%3D 10.1161/hc0902.104353 (Pubitemid 34212626)
96. PM Ridker 2009 Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) J Thromb Haemost 7 Suppl 1 332 339 19630828 1:CAS:528:DC%2BD1MXpvV2itr4%3D 10.1111/j.1538-7836.2009.03404.x
97. WM Vollmer FM Sacks J Ard, et al. 2001 Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial Ann Intern Med 135 1019 1028 11747380 1:CAS:528:DC%2BD38XlvFKltQ%3D%3D (Pubitemid 33151023)
98. FM Sacks LP Svetkey WM Vollmer, et al. 2001 Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group N Engl J Med 344 3 10 11136953 1:STN:280:DC%2BD3M7ksVSqsQ%3D%3D 10.1056/NEJM200101043440101 (Pubitemid 32064838)
99. GA Kelley KS Kelley 2000 Progressive resistance exercise and resting blood pressure: a meta-analysis of randomized controlled trials Hypertension 35 838 843 10720604 1:STN:280:DC%2BD3c7oslCgsQ%3D%3D (Pubitemid 30165335)
100. SP Whelton A Chin X Xin J He 2002 Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials Ann Intern Med 136 493 503 11926784 (Pubitemid 34252283)
101. Major outcomes in moderately hypercholesterolemic 2002 hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2998 3007 10.1001/jama.288.23.2998 (Pubitemid 35471161)
102. PS Sever B Dahlof NR Poulter, et al. 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled tria Lancet 361 1149 1158 12686036 1:CAS:528:DC%2BD3sXis1yqu7o%3D 10.1016/S0140-6736(03)12948-0 (Pubitemid 36398384)
103. RH Knopp M d'Emden JG Smilde SJ Pocock 2006 Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 1478 1485 16801565 1:CAS:528:DC%2BD28XnsVahtbk%3D 10.2337/dc05-2415 (Pubitemid 44127567)
104. HM Colhoun DJ Betteridge PN Durrington, et al. 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685 696 15325833 1:CAS:528: DC%2BD2cXmvFWltrY%3D 10.1016/S0140-6736(04)16895-5 (Pubitemid 39140624)
105. J Shepherd GJ Blauw MB Murphy, et al. 2002 Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 1623 1630 12457784 1:CAS:528:DC%2BD38XovFegt7o%3D 10.1016/S0140-6736(02)11600-X (Pubitemid 35379733)